An exploratory analysis of the association between EORTC QLQ-C30 domains and the progression-free/overall survival in advanced melanoma after 12 weeks of treatment on ipilimumab compared to gp100 in a phase III clinical trial
Authors:
Lee D, Harvey B, Gaudin A-F, Gueron B, Bregman B, Lebbé C, Bonnetain F, Borget I.
Publication Type:
Conference Proceedings – Poster
Publication Name:
16th International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual European Congress
Citation:
Lee D, Harvey B, Gaudin A-F, Gueron B, Bregman B, Lebbé C, Bonnetain F and Borget I. An exploratory analysis of the association between EORTC QLQ-C30 domains and the progression-free/overall survival in advanced melanoma after 12 weeks of treatment on ipilimumab compared to gp100 in a phase III clinical trial. 16th International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual European Congress. Dublin, Ireland. 2-6 November. Poster PCN170.
